Copeland Capital Management LLC boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,172,015 shares of the medical instruments supplier's stock after buying an additional 8,623 shares during the quarter. LeMaitre Vascular accounts for 2.0% of Copeland Capital Management LLC's investment portfolio, making the stock its 4th largest position. Copeland Capital Management LLC owned approximately 5.21% of LeMaitre Vascular worth $107,990,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its holdings in LeMaitre Vascular by 8.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,950 shares of the medical instruments supplier's stock valued at $272,000 after acquiring an additional 228 shares in the last quarter. KBC Group NV raised its holdings in shares of LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock valued at $102,000 after purchasing an additional 410 shares in the last quarter. Linden Thomas Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 5.6% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 34,482 shares of the medical instruments supplier's stock worth $3,177,000 after purchasing an additional 1,834 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of LeMaitre Vascular during the fourth quarter worth $158,000. Finally, Albion Financial Group UT increased its holdings in LeMaitre Vascular by 5.7% in the fourth quarter. Albion Financial Group UT now owns 3,796 shares of the medical instruments supplier's stock valued at $350,000 after buying an additional 204 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.
Insider Transactions at LeMaitre Vascular
In other news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company's stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.79% of the company's stock.
LeMaitre Vascular Stock Up 0.8 %
Shares of LMAT traded up $0.76 during trading hours on Wednesday, reaching $98.22. 44,120 shares of the company traded hands, compared to its average volume of 143,478. The stock has a market capitalization of $2.21 billion, a PE ratio of 53.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.96. The stock has a fifty day simple moving average of $97.02 and a 200 day simple moving average of $93.09. LeMaitre Vascular, Inc. has a fifty-two week low of $57.60 and a fifty-two week high of $109.58.
Analyst Ratings Changes
Several equities analysts have commented on the stock. Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Oppenheimer reaffirmed an "outperform" rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price objective for the company. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular currently has an average rating of "Moderate Buy" and an average target price of $94.57.
Read Our Latest Analysis on LMAT
LeMaitre Vascular Company Profile
(
Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Stories
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
